BOT - Anything but charting, page-6985

It will be a lot more than 1% based on the quality and efficacy of those two phase 3 results. They were incredibly impressive for SB's actual efficacy
and potentially more important as a sales pitch the side effect profile was incredibly low and prescribing physicians love this aspect. They want
to be told how much better a new product is and how safe it is.

Comparisons with NEU are very relevant considereing the long pathways involved, the peaks and the troughs, the naysayers and the cheer squads but as is a truism of the markets, 'the market is always right'.